The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback